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West Nile virus (WNV) was first detected in the
Western Hemisphere in 1999 in New York City. From 1999
through 2004, >16,600 cases of WNV-related illnesses
were reported in the United States, of which >7,000 were
neuroinvasive disease and >600 were fatal. Several
approaches are under way to develop a human vaccine.
Through simulations and sensitivity analysis that incorpo-
rated uncertainties regarding future transmission patterns
of WNV and costs of health outcomes, we estimated that
the range of values for the cost per case of WNV illness
prevented by vaccination was US $20,000–$59,000 (mean
$36,000). Cost-effectiveness was most sensitive to
changes in the risk for infection, probability of symptomatic
illness, and vaccination cost. Analysis indicated that univer-
sal vaccination against WNV disease would be unlikely to
result in societal monetary savings unless disease inci-
dence increases substantially over what has been seen in
the past 6 years.
W
est Nile virus (WNV) was first detected in the
Western Hemisphere in 1999 during an outbreak of
encephalitis in New York City (1). Over the next 6 years
the virus spread across the continental United States, as
well as into Canada, Latin America, and the Caribbean
islands (2,3). From 1999 through 2004, >16,600 WNV ill-
nesses in humans have been reported in the United States;
>7,000 of these were neuroinvasive disease, and >600
were fatal. In 2002 alone, 2,942 cases of neuroinvasive
WNV disease were reported in the United States, which
represents the largest epidemic of neuroinvasive WNV dis-
ease ever recorded (4). Approximately 20% of WNVinfec-
tions in humans result in symptomatic illness, and ≈1% of
infections lead to encephalitis, meningitis, or acute flaccid
paralysis (1). A substantial proportion of persons in whom
severe neuroinvasive WNV disease develops have long-
term disability or die as a result of their infection (5,6). 
WNV is transmitted to humans primarily through the
bite of infected mosquitoes, but transmission through
blood transfusion, through organ donation, and from moth-
er to child have been described (7). Strategies to prevent
WNV infection include avoiding exposure to infected
mosquitoes, reducing the abundance of mosquito vectors,
and screening infected blood donations before transfusion.
Several approaches are under way to develop a safe and
effective human vaccine (8–10). The public health utility
of a new vaccine will depend largely on the incidence, geo-
graphic distribution, and severity of WNV disease in the
United States, as well as the cost of vaccination. We eval-
uated the cost-effectiveness of vaccination against WNV
in the United States from a societal perspective.
Uncertainties regarding the future transmission patterns of
WNV and the costs of health outcomes preclude an exact
estimation of the economic impact of vaccination.
Through probabilistic sensitivity analysis, which incorpo-
rates these uncertainties, we estimated the range of most
likely values for the cost-effectiveness of vaccination and
described the variables that have the most impact on the
economic outcome of vaccination. We also estimated the
likelihood that a universal vaccination program would
result in economic savings. 
Methods
The decision tree used to evaluate the cost-effectiveness
of vaccination compared with no vaccination is shown in
the Figure. Vaccination was assumed to have no effect on
the incidence of infection or the severity of WNV illness
but rather to influence only the proportion of infected per-
sons in whom symptoms would develop. Baseline probabil-
ities for each of the chance nodes in the tree were derived
by reviewing published articles on the incidence, clinical
manifestations, and outcomes of WNV disease as described
in further detail below. We estimated the average cost per
case of WNV illness prevented, that is, average cost-effec-
tiveness ratio (ACER) (online Appendix 1, available from
http://www.cdc.gov/ncidod/EID/vol12no03/05-0782_
app1.htm) by calculating the expected societal costs of
WNV illness with a vaccination strategy, subtracting the
costs of illness with no vaccination, and dividing the
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Time Horizon
We assumed that a single dose of live-attenuated WNV
vaccine would provide immunity for >10 years, as is true
for the currently licensed yellow fever vaccine (10,11). If
an inactivated vaccine were used, 2 or 3 initial doses
would probably be required, and booster doses would
probably be needed every 3 years, as is currently recom-
mended for inactivated Japanese encephalitis vaccine (12).
Both the cost and effectiveness of vaccination were
assumed to be the same whether achieved through a single
live-attenuated vaccine dose or multiple inactivated vac-
cine doses at a lower cost per dose. 
Although the time horizon for risk for illness, protec-
tion from the vaccine, and cost of vaccination was 10
years, we used estimated lifetime costs of disease out-
comes in our model. Thus, we modeled the difference in
lifetime costs of illness that would be incurred by society
during a 10-year period under an immediately implement-
ed universal vaccination strategy compared with no vacci-
nation. 
The probabilities of outcomes and costs modeled are
average probabilities for the entire population, regardless
of age. Our analysis therefore estimates ranges of average
societal costs and outcomes prevented when all people in
the society are vaccinated, regardless of the age at vaccina-
tion or illness. A more detailed analysis of the effect of
vaccinating certain age groups would require estimates of
age-specific risks and costs of outcomes, which are not
readily available for most outcomes in the model. 
Estimation of Costs
The overall cost of WNV illness per person at risk was
calculated as the sum of the average costs for each health
outcome weighted by the probability of occurrence of each
outcome (online Appendix Table, available from http://
www.cdc.gov/ncidod/EID/vol12no03/05-0782.
htm#table_app). Both medical treatment costs and produc-
tivity losses due to illness and death from WNV infection
were included in cost estimates. We considered the follow-
ing health outcomes of WNV infection in our analysis:
asymptomatic infection, uncomplicated febrile illness with
full recovery, neuroinvasive illness (encephalitis, meningi-
tis, or paralysis) with full recovery, neuroinvasive illness
with residual long-term disability, and death. 
Asymptomatic infection was assumed to have no cost.
Estimates of the cost of uncomplicated febrile illness due
to WNV infection were not available so we assumed a cost
of US $1,000 per case, based on 5 days of lost productivi-
ty at $165 per day (13), plus an assumed $175 in medical
costs that included 1 ambulatory care visit, diagnostic
tests, and outpatient medications. Precision of this cost
estimate was not very important since the cost-effective-
ness ratio was not sensitive to the changes in this variable.
The estimated cost per case of neuroinvasive WNV illness
with full recovery ($27,500) was derived from an econom-
ic study conducted during the 2002 WNV epidemic in
Louisiana (14) in which economic costs, rather than
charges, were considered a measure of resources. Our goal
was to measure the forgone benefits that could have been
derived if the resources had been allocated to their next
best use, i.e., the opportunity cost. Charges made by
healthcare providers do not usually reflect the opportunity
costs because of healthcare market imperfections. Charges
were adjusted to economic costs through the use of cost-to-
charge ratios (for details see Appendix 2 in reference 14;
we adjusted 2002 dollars to 2004 dollars, the last year for
which consumer price indices were available at the time of
this study [15,16]). This cost of neuroinvasive illness
included costs of outpatient evaluation, inpatient treat-
ment, rehabilitation treatment, lost productivity of the
patient and caregiver at home, and transportation (online
Appendix Table). Estimates of the cost of residual long-
term disability after neuroinvasive disease were not avail-
able, but many of the disabilities that have been described
after WNV illness are clinically similar to those that result
from acute stroke, and the 2 conditions both affect prima-
rily older males. We therefore used estimates of the life-
time cost of stroke as a proxy for the cost per case of
neuroinvasive WNV illness with residual long-term dis-
ability (17) (1990 dollars adjusted to 2004 dollars [15,16]).
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Figure. Decision tree for vaccination program. WNV, West Nile
virus. The average societal cost due to death from WNV dis-
ease was estimated by using productivity loss tables (13)
and the age distribution of 713 WNV nationwide deaths
reported to the ArboNET database of the Centers for
Disease Control and Prevention (CDC) since 1999 (CDC,
unpub. data). The median age of fatal cases was 77 years
(range 1 month to 99 years). The estimated cost due to
death was $200,000 at a 3% discount rate (2000 dollars
from productivity tables [13] were adjusted to 2004 dollars
[16]). Since short-term costs in our model were randomly
distributed throughout the 10-year time horizon, to simpli-
fy the model, we only discounted the long-term costs, such
as long-term disability costs and costs due to death. For the
short-term costs incurred within the 10-year time horizon,
we assumed our estimates represented the present values of
those costs (online Appendix 2, available from http://www.
cdc.gov/ncidod/EID/Vol12No03/05-0782_ app2.htm). 
Since no human WNV vaccine was licensed at the time
of our evaluation, vaccine costs were not available. Based
on charges in the United States for yellow fever vaccine
(≈$85 per dose), hepatitis A vaccine (≈$75 per dose),
Japanese encephalitis vaccine (≈$315 for a 3-dose series),
and the previously available Lyme disease vaccine (≈$150
for a 3-dose series), we assumed a total baseline vaccina-
tion cost of $100 to include both the actual cost of the vac-
cine and the cost of administering the vaccine. For the
sensitivity analysis focused on the cost of vaccination, we
assumed minimum and maximum vaccination costs of $10
and $150, respectively (see below).  
Estimates of Probabilities for Health Outcomes
Probability of Infection 
Several seroepidemiologic surveys have estimated the
proportion of North American populations who were
infected with WNV during epidemic transmission. The
highest seroprevalence published to date is 2.6% (1). In
2002, during the largest epidemic of WNV neuroinvasive
disease ever described in the United States, 2,942 neuroin-
vasive WNV disease cases were reported from 36 states
and the District of Columbia (total population ≈253.4 mil-
lion). If one assumes a ratio of 1 neuroinvasive case for
every 140 infections, which was the finding of a 1999
household-based seroepidemiologic survey in New York
City (1), this yields an overall estimate of ≈411,880 infec-
tions and an estimated incidence of 0.16 infections per 100
people, or 0.0016 per person per year. Whether WNV epi-
demics will continue to occur in the United States at a sim-
ilar frequency or intensity is unknown, but for this analysis
we assumed that the risk for WNV infection would be
0.0016 per person per year for 10 years. The cumulative
risk for WNV infection over a 10-year period would be 1
– e(–0.0016 × 10) = 0.016. We therefore estimated the baseline
probability of infection as 0.016. For sensitivity analysis
focused on probability of infection, we assumed for the
minimum risk for infection that a person would encounter
only 1 year of WNV transmission, yielding a cumulative
risk of 0.0016 over the 10-year period. For the maximum
risk, we assumed that the risk would be that of yearly epi-
demic transmission such that 2.6% of the population
would be infected each year over the 10-year period, yield-
ing a 10-year cumulative risk of 0.23. Further details
regarding sensitivity analysis are described below. 
Probability of Symptomatic Illness and Vaccine
Effectiveness
We assumed that symptoms of WNV illness will devel-
op in 20% of infected persons and that neuroinvasive dis-
ease will develop in 3.6% of them, which is equivalent to
1 neuroinvasive case for every 140 infections previously
described (1). We also assumed a vaccine effectiveness of
80% in reducing the risk for symptomatic illness.
Probability of Long-term Disability or Death after
Neuroinvasive WNV Disease
Precise data on long-term outcomes from WNV illness
are limited. A study of 19 patients with neuroinvasive
WNV disease found that 2 (11%) died, and of the 17 sur-
vivors, 7 (41%) had recovered fully at the time of dis-
charge, 6 (31%) were discharged without full recovery,
and 4 (24%) were discharged to a long-term care facility
(18). Another study of 57 patients with neuroinvasive dis-
ease found that 10 (18%) eventually died, 13 (23%) were
discharged without support, 14 (25%) were discharged
requiring support, 14 (25%) were discharged to a rehabili-
tation facility or nursing home, 4 (7%) moved in with rel-
atives, and 2 (4%) remained in an acute care facility (5). A
study of 16 patients with neuroinvasive WNV disease
found that 1 patient (6%) died and that 8 months after ill-
ness, 4 (25%) patients required assistance or rehabilitation
and 11 (69%) were functioning independently at home
(19). A survey of 35 patients who had been hospitalized
with WNV illness found that 63% reported full recovery
12 months after illness onset (6). Based on the limited data
from these studies, we assumed that 35% of patients would
have lifelong disability after neuroinvasive WNV disease.
Of 2,942 patients with neuroinvasive WNV disease report-
ed in the United States in 2002, 276 (9%) died (4). For our
model, we assumed a case-fatality ratio of 9%. 
Sensitivity Analysis
To incorporate uncertainties regarding the values of all
input variables, we assigned uniform probability distribu-
tion to all variables, allowing 25% variability around the
baseline values (Table 1). We used @Risk Analysis 2002
software (Palisade Corporation, Newfield, NY, USA) to
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Carlo simulation of the ACER using 5,000 iterations that
covered all combinations of input variable values. The
results provided detailed summary statistics for the ACER
distribution, including the 5th and 95th percentile ranges
of values and the probability that vaccination would result
in societal savings. To further investigate the impact of the
risk for infection and vaccination cost on the ACER, we
ran separate simulations in which the minimum, baseline,
and maximum values for these variables described in the
corresponding sections were fixed, while all other vari-
ables were allowed to vary according to their prespecified
uniform distributions.
Results
Using baseline values of all input variables, without
accounting for uncertainties, the average cost per case of
WNV illness prevented would be ≈$34,200. At a cost of
$8.7 billion in a hypothetical population of 100 million peo-
ple, vaccination would prevent 256,000 cases of WNV ill-
ness, including 9,216 cases of neuroinvasive disease, 2,935
cases of lifetime disability, and 829 deaths during a 10-year
period. Under these assumptions, universal vaccination
would yield societal savings if the cumulative incidence of
WNV infection over a 10-year period were >0.13 (≈1.4%
of the population infected each year), the cost of vaccina-
tion were <$12.8, or the cost of lifelong disability were
>$3.2 million (≈15 times higher than the baseline estimate).
The simulation results accounting for uncertainties in
all input variables are shown in Table 2. The median of the
ACER distribution was $35,000 per case of WNV illness
prevented. The 5th and 95th percentiles for the ACER were
$59,000 and $20,000, respectively. 
To identify the sensitivity of the output to all input dis-
tributions, we used @Risk sensitivity analysis with a
regression in which the dependent variable was the output
variable, i.e., ACER, and the independent variables were
the input variables presented as @Risk uniform distribu-
tion functions (Table 1). Each iteration represented an
observation for the regression. The coefficients calculated
for each input variable measured the sensitivity of the out-
put to that particular input distribution. The results indicat-
ed that ACER was most sensitive to the changes in the risk
for infection, probability of symptomatic illness, and vac-
cination cost (Table 3). A 1 standard deviation (SD)
increase in the probability of symptomatic illness
increased the ACER by an SD of 0.65, while a 1 SD
increase in the probability of infection or the vaccination
cost increased the ACER by an SD of 0.5. Changes in the
other variables had little or no impact on ACER (Table 3).
The results of the sensitivity analysis focused separate-
ly on risk for infection and vaccination cost are shown in
Table 4. The probability that vaccination would yield soci-
etal savings changed from 0% to 98% when the 10-year
cumulative risk for WNV infection changed from 0.016 to
0.230, and from 0% to 76% as the vaccination cost
decreased from $150 to $10.
Discussion
The economic impact of a vaccination strategy is a
determinant of the public health decision regarding
whether or not to recommend vaccination, but it is certain-
ly not the only determinant of sound public health vaccina-
tion policy. It is also not imperative that a vaccination
program result in monetary savings for it to be cost-effec-
tive compared with other public health interventions.
Societies and people are willing to pay for preventing dis-
ease, as indicated by the implementation of preventive
interventions that do not result in economic savings, and
most relevant, the willingness to pay for expensive vac-
cines (20–22). However, as public health implications of
vaccination programs are considered, we must have some
understanding of the resources that might be expended.
Vaccination would be most appealing if it is likely to safe-
ly prevent disease and save society money, or at least have
a relatively low cost per case of illness prevented. 
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gram to prevent WNV disease would be unlikely to result
in societal monetary savings unless the incidence of the
disease increases substantially over what has been seen in
the past 6 years, or the cost of vaccination were <$12 per
person vaccinated. The risk for WNV infection, probabili-
ty of symptomatic illness after infection, and cost of vac-
cine appeared to have the greatest influence on the
cost-effectiveness outcome. Within the range of possible
values used in our model, variations in vaccine effective-
ness, cost of WNV illness, and probabilities of various
health outcomes did not lead to considerable change in the
cost-effectiveness. 
The future patterns of WNV transmission in North
America cannot be accurately predicted. The virus was
first detected in North America in 1999, and the epidemi-
ology of WNV illness in the Western Hemisphere contin-
ues to evolve. The antigenically related flaviviruses St.
Louis encephalitis virus (SLEV) and Japanese encephalitis
virus (JEV) demonstrate different patterns of transmission
that WNV could assume; SLEV is sporadically transmitted
in North America with intense epidemics separated by
years of low-level transmission, while JEV occurs in Asia
with annual epidemics of intense transmission. If WNV
assumes a transmission pattern in North America similar to
that of JEV in Asia, then vaccination is likely to be a much
more appealing public health prevention strategy and is
likely to be more cost-effective than if WNV transmission
follows the pattern of SLEV. As WNV spreads southward
into Latin America, increased incidence may be seen with
less protection from mosquitoes provided by air condition-
ing and screens (23). If intense transmission is seen in
these areas, vaccination may be the most cost-effective
prevention strategy, but unless the vaccine cost is low, it
may still be too expensive for local economies. 
WNV infection may cause severe untreatable neurolog-
ic disease. While the risk is highest in the elderly, severe
disease does occur among young adults and children
(4,24). The more severe, untreatable manifestations of
WNV infection would compel interest in vaccine develop-
ment and use even if vaccination is expensive, particularly
since current prevention strategies such as personal repel-
lent use or environmental reduction of mosquito abun-
dance may not be consistently implemented (25). The
effectiveness of these other prevention strategies is diffi-
cult to conclusively demonstrate and estimates of their
cost-effectiveness have not been published. Vaccination
may reduce the expenditures for mosquito control in cer-
tain areas, but we did not include this possible effect in our
model. If alternate prevention costs were reduced by vac-
cination, we would expect this to improve the cost-effec-
tiveness of vaccination from the societal perspective. 
Our results provide a general assessment of the likely
economic implications of universal vaccination against
WNV and an indication of which parameters have the
greatest influence on the cost-effectiveness of vaccination.
A safe and effective vaccine may prove to be the most
effective, and perhaps the most cost-effective, strategy to
prevent severe WNV illness. The economic impact of vac-
cination will depend mostly on the risk for WNV infection,
probability of symptomatic illness after infection, and the
cost of vaccination.
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